Extract from “Reject the TPP in the public interest—Jomo Kwame Sundaram”

Meanwhile, contrary to conventional wisdom, there is growing evidence that IPRs hardly promote research, but may actually impede innovation. In fact, specific TPP provisions will limit competition and raise consumer prices. Thus, the TPP will slow innovation besides threatening public health and the common good.

The TPP will strengthen IPRs for big pharmaceutical, information technology, media and other companies which make their money from the monopoly status conferred by such rights. For example, the TPP would allow pharmaceutical companies to have longer monopolies on patented medicines, keep cheaper generic medicines off the market, and block the development and availability of similar new medicines.

Loading data

Welcome to TPP Debate!
What's your stance?

TPPDebate.org is a crowd-sourced platform to debate the Trans-Pacific Partnership Agreement (TPP). What does everyone think about the TPP? What is your stance?